Maryland House Bill HB880

Maryland 2024 Regular Session

• Introduced: 2/2/24
• Refer: 2/2/24

Caption

Pharmacy Benefits Administration - Maryland Medical Assistance Program and Pharmacy Benefits Managers

Impact

The legislation is expected to have significant implications on the current statutes regarding pharmacy benefits management. By establishing a minimum reimbursement level, the bill seeks to protect pharmacies from inadequate compensation that may affect their ability to serve low-income patients. Advocates for the bill argue that it promotes fair practices in the pharmaceutical industry and helps maintain a robust network of pharmacies that are essential for patient care under the medical assistance program.

Summary

House Bill 880 is an emergency bill that addresses the administration of pharmacy benefits in relation to the Maryland Medical Assistance Program. The primary aim of the bill is to alter the reimbursement levels that pharmacy benefits managers (PBMs) are required to provide to pharmacies. It mandates that the reimbursement be at least equal to the National Average Drug Acquisition Cost (NADAC) of generic products plus a professional dispensing fee based on the most recent in-state cost of dispensing survey. This change is intended to ensure fair compensation for pharmacies participating in the state's medical assistance program and to improve access to medication for beneficiaries.

Contention

Opposition to HB 880 arises from concerns regarding the potential financial impact on pharmacy benefits managers and their ability to negotiate prices with pharmacies. Critics argue that increased reimbursement levels may lead to higher costs for managed care organizations and, subsequently, the state. There are also fears that this could influence PBMs' operational strategies, potentially resulting in increased drug prices for consumers. The balance between ensuring pharmacy sustainability and managing costs remains a contentious issue among stakeholders.